RxDoctor Payments Data

Katherine Roth, MD

Neurology · Port Jefferson Station, NYNPI 1083695233

Payments from drug & device makers

$33,955in general payments, 2019–2025

Across 1,325 payments — averaging $25.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$4K
  • Amgen$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Lundbeck LLC$2K
  • AstraZeneca$2K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$1080%
  • Food & beverage$33,60499%
  • Education$930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)217$4,053
Biogen146$3,616
Amgen(2 entities)85$2,436
Teva Pharmaceuticals USA, Inc.83$2,250
Lundbeck LLC87$2,175
AstraZeneca(2 entities)44$2,130
UCB, Inc.85$1,875
Amneal Pharmaceuticals LLC53$1,498
Pfizer59$1,257
Argenx US, Inc.44$1,150
Harmony Biosciences LLC23$1,065
Novartis44$876
SK Life Science, Inc.33$831
Sanofi32$813
EMD Serono, Inc.17$744
Genentech USA, Inc.16$525
Neurelis, Inc.21$486
Neurocrine Biosciences, Inc.15$472
Axsome Therapeutics, Inc.12$447
Supernus Pharmaceuticals, Inc.19$399
Takeda Pharmaceuticals U.S.A., Inc.13$387
Lilly USA, LLC17$338
Avanir Pharmaceuticals, Inc.7$249
Grifols USA, LLC10$238
Bristol Myers Squibb10$225
Otsuka America Pharmaceutical, Inc.15$221
Biohaven Pharmaceutical Holding Company Ltd.10$207
Medtronic3$203
Biohaven Pharmaceuticals, Inc.8$199
E.r. Squibb & Sons, L.L.C.4$199
Daiichi Sankyo Inc.4$188
Merck9$187
Upsher-smith Laboratories LLC8$157
Kyowa Kirin, Inc.2$154
Johnson & Johnson(2 entities)3$141
Bausch Health US, LLC7$135
Sunovion Pharmaceuticals Inc.1$125
Therapeuticsmd, Inc.1$125
Acorda Therapeutics, Inc6$123
Currax Pharmaceuticals LLC7$122
Merz Pharmaceuticals, LLC3$89
Assertio Therapeutics, Inc.4$81
Eisai Inc.4$81
Collegium Pharmaceutical, Inc.3$69
Impel Pharmaceuticals Inc.3$57
Validus Pharmaceuticals LLC1$50
Scilex Pharmaceuticals Inc.2$43
Livanova USA, Inc.2$42
Virtus Pharmaceuticals LLC2$38
Jazz Pharmaceuticals Inc.2$37
Kowa Pharmaceuticals America, Inc.2$36
Banner Life Sciences, LLC2$34
Biodelivery Sciences International, Inc.2$33
Sentynl Therapeutics, Inc.2$32
Forte Bio-pharma LLC1$32
CSL Behring2$32
Promius Pharma LLC2$27
Catalyst Pharmaceuticals, Inc.1$25
GE HealthCare1$23
Redhill Biopharma Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,955 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$257,616
Medicare patients
705
Services billed
1,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen20$115,815
AptiomEslicarbazepine Acetate43$78,548
CopaxoneGlatiramer Acetate11$76,999
UbrelvyUbrogepant38$59,016
RexultiBrexpiprazole21$30,431
VraylarCariprazine Hcl12$16,624
BriviactBrivaracetam12$16,128
QuliptaAtogepant14$14,542
XcopriCenobamate13$12,834
OxycontinOxycodone Hcl21$10,867
DilantinPhenytoin Sodium Extended25$8,411
Ambien CrZolpidem Tartrate12$7,612
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen171$7,215
Mycophenolate Mofetil13$4,529
Levetiracetam198$4,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Vraylar, Qulipta$4,053$90,18264 claims
Sunovion Pharmaceuticals Inc.Aptiom$125$78,54843 claims
Teva Pharmaceuticals USA, Inc.Copaxone$2,250$76,99911 claims
Otsuka America Pharmaceutical, Inc.Rexulti$221$30,43121 claims
UCB, Inc.Briviact$1,875$16,12812 claims
SK Life Science, Inc.Xcopri$831$12,83413 claims
PfizerDilantin$1,257$8,41125 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$1,498$5,67628 claims
Upsher-smith Laboratories LLCTopiramate$157$912112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →